Salud financiera de hoja de balance de Inhibitor Therapeutics
Salud financiera controles de criterios 6/6
Inhibitor Therapeutics has a total shareholder equity of $4.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $7.2M and $3.0M respectively.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$7.10m |
| Patrimonio | US$4.14m |
| Total pasivo | US$3.04m |
| Activos totales | US$7.17m |
Actualizaciones recientes sobre salud financiera
No hay actualizaciones
Recent updates
Análisis de la situación financiera
Pasivos a corto plazo: INTI's short term assets ($7.2M) exceed its short term liabilities ($35.5K).
Pasivo a largo plazo: INTI's short term assets ($7.2M) exceed its long term liabilities ($3.0M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: INTI is debt free.
Reducción de la deuda: INTI had no debt 5 years ago.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: INTI has sufficient cash runway for more than a year based on its current free cash flow.
Pronóstico de cash runway: INTI has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 42.2% each year.